Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 443 for:    MDX 1106 and MDX 010
Previous Study | Return to List | Next Study

Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01024231
Recruitment Status : Completed
First Posted : December 2, 2009
Results First Posted : March 22, 2021
Last Update Posted : March 22, 2021
Sponsor:
Collaborators:
Medarex
Ono Pharma USA Inc
Information provided by (Responsible Party):
Bristol-Myers Squibb

Brief Summary:
The purpose of this study is to determine the safety and tolerability of treatment with BMS-936558 (MDX-1106) in combination with Ipilimumab (BMS-734016) when given at the same time or as a sequenced regimen in subjects with unresectable Stage III or Stage IV malignant melanoma (MEL)

Condition or disease Intervention/treatment Phase
Malignant Melanoma Drug: BMS-936558 (MDX1106-04) Drug: Ipilimumab Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 127 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1b, Open-label, Multicenter, Multidose, Dose-escalation Study of BMS-936558 (MDX-1106) in Combination With Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma
Actual Study Start Date : December 14, 2009
Actual Primary Completion Date : February 4, 2014
Actual Study Completion Date : April 1, 2019

Resource links provided by the National Library of Medicine

MedlinePlus Genetics related topics: Melanoma
MedlinePlus related topics: Melanoma

Arm Intervention/treatment
Experimental: Cohort 1: BMS-936558 (0.3 mg/kg)+Ipilimumab (3 mg/kg)

BMS-936558 (MDX1106-04) 0.3 mg/kg solution, 60 minutes intravenous infusion every 3 (q3) weeks for 21 weeks in induction and every 12 (q12) weeks for 84 weeks in maintenance

Ipilimumab (BMS-734016) 3 mg/kg solution, 90 minutes intravenous infusion q3 weeks for 9 weeks in induction and q12 weeks for 84 weeks in maintenance

Drug: BMS-936558 (MDX1106-04)
Other Name: Nivolumab

Drug: Ipilimumab
Other Name: BMS-734016

Experimental: Cohort 2: BMS-936558 (1 mg/kg)+Ipilimumab (3 mg/kg)

Ipilimumab (BMS-734016) 3 mg/kg solution, 90 minutes intravenous infusion, q3 weeks for 9 weeks in induction and q12 weeks for 84 weeks in maintenance

BMS-936558 (MDX1106-04) 1 mg/kg solution, 60 minutes intravenous infusion, q3 weeks for 21 weeks in induction and q12 weeks for 84 weeks in maintenance

Drug: BMS-936558 (MDX1106-04)
Other Name: Nivolumab

Drug: Ipilimumab
Other Name: BMS-734016

Experimental: Cohort 3: BMS-936558 (3 mg/kg)+Ipilimumab (3 mg/kg)

Ipilimumab (BMS-734016) 3 mg/kg solution, 90 minutes intravenous infusion, q3 weeks for 9 weeks in induction and q12 weeks for 84 weeks in maintenance

BMS-936558 (MDX1106-04) 3 mg/kg solution, 60 minutes intravenous infusion, q3 weeks for 21 weeks in induction and q12 weeks for 84 weeks in maintenance

Drug: BMS-936558 (MDX1106-04)
Other Name: Nivolumab

Drug: Ipilimumab
Other Name: BMS-734016

Experimental: Cohort 4: BMS-936558 (10 mg/kg)+Ipilimumab (3 mg/kg)

BMS-936558 (MDX1106-04) 10 mg/kg solution, 60 minutes intravenous infusion, q3 weeks for 21 weeks in induction and q12 weeks for 84 weeks in maintenance

Ipilimumab (BMS-734016) 3 mg/kg solution, 90 minutes intravenous infusion, q3 weeks for 9 weeks in induction and q12 weeks for 84 weeks in maintenance

Drug: BMS-936558 (MDX1106-04)
Other Name: Nivolumab

Drug: Ipilimumab
Other Name: BMS-734016

Experimental: Cohort 5: BMS-936558 (10 mg/kg)+Ipilimumab (10 mg/kg)

BMS-936558 (MDX1106-04) 10 mg/kg solution, 60 minutes intravenous infusion, q3 weeks for 21 weeks in induction and q12 weeks for 84 weeks in maintenance

Ipilimumab (BMS-734016) 10 mg/kg solution, 90 minutes intravenous infusion, q3 weeks for 9 weeks in induction and q12 weeks for 84 weeks in maintenance

Drug: BMS-936558 (MDX1106-04)
Other Name: Nivolumab

Drug: Ipilimumab
Other Name: BMS-734016

Experimental: Cohort 6: BMS-936558 (1 mg/kg)
BMS-936558 (MDX1106-04) 1 mg/kg solution, 60 minutes intravenous infusion, once q2 weeks for a total maximal duration of 96 weeks
Drug: BMS-936558 (MDX1106-04)
Other Name: Nivolumab

Experimental: Cohort 7: BMS-936558 (3 mg/kg)
BMS-936558 (MDX1106-04) 3 mg/kg solution, 60 minutes intravenous infusion, once q2 weeks for a total maximal duration of 96 weeks
Drug: BMS-936558 (MDX1106-04)
Other Name: Nivolumab

Experimental: Cohort 8: Nivolumab+Ipilimumab

Nivolumab 1 mg/kg and Ipilimumab 3 mg/kg solution intravenously q3 weeks, 4 doses for 12 weeks

Followed by Nivolumab 3 mg/kg solution alone intravenously q2 weeks, 48 doses for a maximum of 96 weeks

Drug: BMS-936558 (MDX1106-04)
Other Name: Nivolumab

Drug: Ipilimumab
Other Name: BMS-734016




Primary Outcome Measures :
  1. Number of Participants With an Adverse Event (AE) [ Time Frame: Up to 3 years ]
    incidence of all cause and treatment related adverse events

  2. Number of Participants With a Serious Adverse Event (AE) [ Time Frame: Up to 3 years ]
    incidence of all cause and treatment related serious adverse events

  3. Number of Participants With an Adverse Event (AE) Which Lead to Discontinuation [ Time Frame: Up to 3 years ]
    incidence of all cause and treatment related adverse events which lead to discontinuation

  4. Number of Deaths [ Time Frame: Up to 3 years ]
    incidence of all cause and treatment related deaths

  5. Number of Participants With Select AEs [ Time Frame: Up to 3 years ]
    incidence of all cause and treatment related Adverse events in certain organ systems

  6. Laboratory Abnormalities: Specific Liver Tests [ Time Frame: Up to 3 years ]
    Number of Participants with On-Treatment Laboratory Abnormalities in Specific Liver Tests Aspartate aminotransferase (AST) Alanine aminotransferase (ALT) Upper Limit of Normal (ULN)

  7. Laboratory Abnormalities: Specific Thyroid Tests [ Time Frame: Up to 3 years ]
    Number of Participants with On-Treatment Laboratory Abnormalities in Specific Thyroid Tests Free T3 (FT3) Free T4 (FT4) Lower Limit of Normal (LLN)


Secondary Outcome Measures :
  1. Objective Response Rate [ Time Frame: Up to 3 years ]
    the total number of participants whose best overall response (BOR) is either irCR or irPR divided by the total number of response-evaluable participants.

  2. Time to Response [ Time Frame: Up to 3 Years ]
    the time from the first dose of study drug until the first documentation of irCR or irPR, as related to current database lock date or most current tumor measurement

  3. Duration of Response [ Time Frame: from the first documented response (irCR or irPR) until progression or death ]
    the time from the first documented response (irCR or irPR) until progression or death, whichever occurs first. For participants who did not progress or die, duration of response will be censored on the date of the last tumor assessment.

  4. Progression Free Survival [ Time Frame: 156 weeks ]
    the time from the first dose to the first observation of disease progression or death due to any cause. If a participant has not progressed or died at the time of analysis, PFS will be censored on the date of the last disease assessment. Participants who did not have any on-study tumor assessments and did not die will be censored on the date of the first dose of study medication.

  5. Number of Participants With an Anti-Drug Antibody (ADA) Response for Nivolumab (Nivo) and Ipilimumab (Ipi) [ Time Frame: Up to 3 years ]
    Serum samples will be collected to evaluate the development of antibodies to BMS-936558 and to ipilimumab.

  6. Peak and Trough Concentrations [ Time Frame: Up to 64 Weeks ]
    The peak and trough concentrations of BMS-936558 (MDX-1106) and ipilimumab in participants with quantifiable data



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

  • Histologic diagnosis of malignant melanoma (MEL)
  • Measurable unresectable Stage III or IV MEL
  • ECOG performance status score of 0 or 1
  • Life expectancy ≥4 months
  • For those enrolled in amendment 5 and later, tumor tissue (archival or recent acquisition) must be available
  • For Cohorts 1-5, subjects may have been treated with up to 3 prior systemic standard treatments for metastatic melanoma not including any post-incisional adjuvant therapy. Subjects may be treatment naïve. All metastatic melanoma regardless of primary site of disease will be allowed
  • For Cohorts 6-7, subjects may have been treated with up to 3 prior systemic standard treatments for metastatic melanoma; this does not include any post-incisional adjuvant therapy. Specifically, subjects must have received ≥3 doses of Ipilimumab therapy and the last dose having been administered within 4-12 weeks of initiation of study treatment

Exclusion Criteria:

  • History of severe hypersensitivity reactions to other mAbs
  • Prior malignancy active within the previous 2 years except for localized cancers that are considered to have been cured and in the opinion of the investigator present a low risk for recurrence
  • Active autoimmune disease or a history of known or suspected autoimmune disease
  • History of recently active diverticulitis or symptomatic peptic ulcer disease and history of adrenal insufficiency
  • Regular narcotic analgesia
  • Active, untreated central nervous system metastasis
  • For subjects enrolled in Cohorts 1-5, prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137 or anti-CTLA-4 antibody
  • For subjects enrolled in Cohorts 6-7, prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, or anti-CD137 antibodies
  • Any non-oncology vaccine therapy used for prevention of infectious disease
  • Concomitant therapy with any other anti-cancer therapy, concurrent medical conditions requiring use of immunosuppressive medications or use of other investigational drugs
  • Positive tests for human immunodeficiency virus (HIV), acquired immunodeficiency syndrome (AIDS), hepatitis B, hepatitis C
  • Subjects weighing ≥125 kg are excluded from Cohort 5
  • Subjects in Cohorts 6 and 7 must have received Ipilimumab monotherapy immediately prior to study entry, but must not have received that Ipilimumab as part of a clinical trial
  • Subjects with ocular melanoma are excluded from Cohort 8

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01024231


Locations
Layout table for location information
United States, Connecticut
Yale University School Of Medicine
New Haven, Connecticut, United States, 06520
United States, District of Columbia
Medstar Georgetown-Lombardi Comprehensive Cancer Center
Washington, District of Columbia, United States, 20007
United States, New York
Memorial Sloan Kettering Nassau
New York, New York, United States, 11065
United States, Pennsylvania
Hillman Cancer Research Pavilion
Pittsburgh, Pennsylvania, United States, 15232
Sponsors and Collaborators
Bristol-Myers Squibb
Medarex
Ono Pharma USA Inc
Investigators
Layout table for investigator information
Study Director: Bristol-Myers Squibb Bristol-Myers Squibb
  Study Documents (Full-Text)

Documents provided by Bristol-Myers Squibb:
Statistical Analysis Plan  [PDF] August 20, 2014
Study Protocol  [PDF] May 10, 2017

Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Bristol-Myers Squibb
ClinicalTrials.gov Identifier: NCT01024231    
Other Study ID Numbers: CA209-004
(MDX1106-04) ( Other Identifier: Medarex )
First Posted: December 2, 2009    Key Record Dates
Results First Posted: March 22, 2021
Last Update Posted: March 22, 2021
Last Verified: March 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Nivolumab
Ipilimumab
Melanoma
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Nerve Tissue
Nevi and Melanomas
Antineoplastic Agents, Immunological
Antineoplastic Agents